Co-Diagnostics Stock Plummets 29% Amid $4.1M ATM Equity Raise and Global JV Expansions

CO DIAGNOSTICS INC (NASDAQ: CODX) Overview

CO DIAGNOSTICS INC (ticker: CODX, Korean: 코 다이어그노스틱스) is a Salt Lake City–based molecular diagnostics company founded in 2013. Its primary offering is the Co-Dx™ PCR platform—a portable, on-site real-time PCR system that utilizes proprietary Co-Primers® chemistry along with cloud-enabled analysis. The platform supports applications in at-home testing, point-of-care diagnostics, and research, with solutions that encompass infectious disease testing, vector control, and agricultural genomics.

Metric	Value
Share Price (10/28/2025)	$0.8902
1-Day Change	–29.35 %
Trading Volume	5,192,199
Exchange	NASDAQ Capital Market
Shares Outstanding	~45.3 million (non-affiliates)
Market Cap (non-affiliates)	$28.9 million

Corporate Structure

Co-Diagnostics employs between 51 and 200 people, including a team of scientists focused on multiplex PCR assay development. The company operates its headquarters in Salt Lake City, Utah, and holds multiple patents related to Co-Primers® technology. The leadership team is headed by CEO Dwight Egan.

PCR Diagnostics by National Cancer Institute

Recent Developments and News

• October 20, 2025 – SEC Filings
  • Filed Form 8-K reporting material items under Sections 1.01, 1.02, and 9.01.
  • Filed a prospectus supplement (Form 424B5) to offer up to $4,086,645 of common stock as part of an Equity Distribution Agreement with Maxim Group LLC, with a recent trading price of $0.3242 per share (as of October 17, 2025).

• September 30, 2025 – SEC Form 8-K
  • Reported material corporate changes under Items 7.01 and 9.01 (details not publicly excerpted).

• March 3, 2025 – Nasdaq Live Interview
  • CEO Dwight Egan participated in an interview with Nasdaq host Kristina Ayanian at the Silicon Slopes Summit.

• February 4, 2025 – CoSara Diagnostics Joint Venture
  • Co-Diagnostics announced its joint venture with CoSara Diagnostics Pvt. Ltd. to host a Holistic Cancer Awareness lecture series in India.

• LinkedIn Announcement – Saudi JV
  • Partnered with Arabian Eagle Manufacturing to launch CoMira Diagnostics in Saudi Arabia, supporting local production of the Co-Dx™ PCR platform.

• Utah Business Awards 2025
  • Recognized as an honoree in Healthcare & Life Sciences for the Co-Dx™ PCR platform.

Financial and Strategic Analysis

Co-Diagnostics generates revenue from the sales of PCR instruments, reagent kits, and licensing of Co-Primers® technology. The prospectus supplement filed on October 20, 2025, facilitates raising up to $4.1 million through at-the-market offerings, potentially funding:

• Ongoing development of at-home and point-of-care PCR tests
• Expansion of manufacturing capacity and regulatory submissions
• Working capital to assist global sales and marketing activities

Despite a 29.35 % decline in share price on October 28, trading volume surpassed 5 million shares, indicating notable investor activity surrounding the executive filings. With an estimated market capitalization of $28.9 million for non-affiliate shares, the company’s valuation remains linked to the demand for PCR testing and regulatory approvals for new assays.

Market Position and Industry Context

CO Diagnostics operates in the molecular diagnostics market, characterized by a focus on speed, accuracy, and portability. The compact Co-Dx™ Box cycler completes real-time PCR testing in approximately 30 minutes, addressing the needs of remote or resource-limited environments. To date, upwards of 34 million real-time PCR tests have been sold. Strategic partnerships—such as the joint ventures with CoMira Diagnostics in Saudi Arabia and CoSara Diagnostics in India—enhance local manufacturing capabilities and market access.

TL;DR

On October 20, 2025, Co-Diagnostics filed an 8-K and a Form 424B5 to enable up to $4.1 million in at-market equity offerings priced at $0.3242 per share (October 17, 2025). The company’s stock (NASDAQ: CODX) was reported at $0.8902 on October 28, 2025, reflecting a decrease of 29.35 % on a volume of 5.19 million shares. Recent initiatives include joint ventures in Saudi Arabia (CoMira Diagnostics) and India (CoSara Diagnostics), alongside ongoing developments for at-home and point-of-care PCR platforms. Future projections depend on the successful execution of capital raises, regulatory approvals for new assays, and broader adoption of the Co-Dx™ platform in global markets.